Home » Stocks » AFIB

Acutus Medical, Inc. (AFIB)

Stock Price: $26.00 USD 0.31 (1.21%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
Market Cap 710.77M
Revenue (ttm) 6.56M
Net Income (ttm) n/a
Shares Out 16.08M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $26.00
Previous Close $25.69
Change ($) 0.31
Change (%) 1.21%
Day's Open 25.63
Day's Range 25.02 - 26.26
Day's Volume 220,508
52-Week Range 22.87 - 37.65

News

Hide News
GlobeNewsWire - 1 week ago

CARLSBAD, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagno...

GlobeNewsWire - 3 weeks ago

CARLSBAD, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagno...

About AFIB

Acutus Medical, an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. It offers AcQMap console and workstation, an advanced imaging, navigation, and mapping system for physicians to map, treat, re-map, and adjust additional therapy as needed; and Patient Electrode Kit that is required in every procedure to provide cardiac signals, catheter localization, and AcQMap system grounding. The company also provid... [Read more...]

Industry
Medical Devices
IPO Date
Aug 6, 2020
Stock Exchange
NASDAQ
Ticker Symbol
AFIB
Full Company Profile

Financial Performance

In 2019, Acutus Medical's revenue was $2.84 million, an increase of 30.93% compared to the previous year's $2.17 million. Losses were -$97.04 million, 102.6% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Acutus Medical stock is "Buy." The 12-month stock price forecast is 34.75, which is an increase of 33.65% from the latest price.

Price Target
$34.75
(33.65% upside)
Analyst Consensus: Buy